文献速递骨质疏松与代谢性骨病

Medicare按服务收费覆盖的绝经后女性骨质疏松治疗模式与长期持续性

Treatment patterns and long-term persistence with osteoporosis therapies in women with Medicare fee-for-service (FFS) coverage.
PubMed 文献 · Osteoporos Int · 2021-06-07

这项回顾性队列研究利用美国Medicare骨质疏松100%样本的行政索赔数据,评估了2011至2014年间启动地舒单抗、口服/静脉双膦酸盐或雷洛昔芬的绝经后女性的长期用药持续性。在随访至少36个月且使用地舒单抗或口服双膦酸盐的女性中,地舒单抗1年、2年、3年持续率分别为73%、50%、38%,均高于口服双膦酸盐的39%、25%、17%。研究结论认为地舒单抗持续性优于其他抗骨吸收药物,首年持续可预测长期持续,但总体持续性欠佳。

要点

  • 地舒单抗3年持续率38%,高于口服双膦酸盐的17%。
  • 所有治疗组持续性随时间下降,地舒单抗在≥18个月各时段最高。
  • 首年坚持用药者更可能在此后年份继续保持。

核心结论

  • 地舒单抗使用者的用药持续性长于口服双膦酸盐等其他抗骨吸收药物。
  • 首年持续用药可能预测长期持续用药。
  • 骨质疏松药物总体持续性欠佳,可能影响骨折风险,需改善首年持续性。

研究设计与样本

  • 回顾性队列研究,使用Medicare骨质疏松100%样本的行政索赔数据。
  • 纳入2011至2014年间启动地舒单抗、口服/静脉双膦酸盐或雷洛昔芬且具有至少1年(唑来膦酸14个月)基线覆盖的绝经后女性。
  • 共纳入口服双膦酸盐318,419例(78%为阿仑膦酸钠)、地舒单抗145,056例、静脉双膦酸盐48,066例、雷洛昔芬31,400例。
  • 平均年龄从雷洛昔芬75.5岁至地舒单抗78.5岁。

主要发现

  • 在随访至少36个月的女性中(地舒单抗N=25,107;口服双膦酸盐N=79,710),地舒单抗与口服双膦酸盐持续率分别为1年73% vs. 39%、2年50% vs. 25%、3年38% vs. 17%。
  • 所有治疗组持续性随时间下降,地舒单抗使用者在18个月及之后每个随访时间间隔的持续性最高。
  • 使用地舒单抗、口服双膦酸盐或雷洛昔芬的女性,若在某一年持续用药,则更可能在此后一年继续保持。

临床怎么用

  • 临床选择抗骨吸收药物时可考虑地舒单抗在长期持续性方面的优势。
  • 应重视首年用药持续性,将其作为长期依从性的预测窗口。
  • 针对骨质疏松药物总体持续性欠佳,需采取措施改善首年持续用药以可能降低骨折风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Osteoporosis, a chronic disease, requires long-term therapy. In Medicare-insured women, denosumab persistence was higher than oral bisphosphonate persistence over up to 3 years of follow-up. Longer-term persistence was higher among women who persisted in the first year of therapy. INTRODUCTION: Osteoporosis, a chronic, progressive disease, requires long-term therapy; this study assessed long-term persistence with anti-resorptive therapies in postmenopausal women. METHODS: This retrospective cohort study used administrative claims for women with data in the 100% Medicare osteoporosis sample who initiated (index date) denosumab, oral/intravenous (IV) bisphosphonate, or raloxifene between 2011 and 2014 and who had ≥ 1 year (zoledronic acid: 14 months) of pre-initiation medical/pharmacy coverage (baseline). Persistence was assessed from index date through end of continuous coverage, post-index evidence of censoring events (e.g., incident cancer), death, or end of study (December 31, 2015). RESULTS: The study included 318,419 oral bisphosphonate users (78% alendronate), 145,056 denosumab users, 48,066 IV bisphosphonate users, and 31,400 raloxifene users; mean age ranged from 75.5 years (raloxifene) to 78.5 years (denosumab). In women with at least 36 months of follow-up (denosumab N = 25,107; oral bisphosphonates N = 79,710), more denosumab than oral bisphosphonate initiators were persistent at 1 year (73% vs. 39%), 2 years (50% vs. 25%), and 3 years (38% vs. 17%). Persistence decreased over time for all treatment groups, with denosumab users having the highest persistence in every follow-up time interval at or after 18 months. Women using denosumab, oral bisphosphonates, or raloxifene who persisted in a given year were more likely to remain persistent through the subsequent year. CONCLUSIONS: Denosumab users persisted longer with therapy than women using other anti-resorptive medications, including oral bisphosphonates. Early persistence may predict long-term persistence. Overall persistence with osteoporosis medications is suboptimal and may impact fracture risk. Efforts to improve first year persistence are needed.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Singer AJ, Liu J, Yan H, et al. Treatment patterns and long-term persistence with osteoporosis therapies in women with Medicare fee-for-service (FFS) coverage. Osteoporos Int. 2021. PMID: 34095966. doi:10.1007/s00198-021-05951-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。